Viral Infections of Humans 2022
DOI: 10.1007/978-1-4939-9544-8_25-1
|View full text |Cite
|
Sign up to set email alerts
|

Paramyxoviruses: Parainfluenza Viruses

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
2

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 310 publications
0
3
0
Order By: Relevance
“…Due to laboratory assay limitations (Table S1), we grouped epidemiologically distinct strains into one incidence time series each for hCoV 229E and hCoV OC43 (hereon hCoV 229E + OC43), hCoV HKU1 and hCoV NL63 (hCoV HKU1 + NL63), hPIV 1 and hPIV 2 (hPIV 1 + 2), hPIV 3 and hPIV 4 (hPIV 3 + 4), hRV, and AdV. hPIV 3 likely comprises most of hPIV 3 + 4 incidence because hPIV 4 infections are detected infrequently and tend to be mild or asymptomatic ( 24 ).…”
Section: Resultsmentioning
confidence: 99%
“…Due to laboratory assay limitations (Table S1), we grouped epidemiologically distinct strains into one incidence time series each for hCoV 229E and hCoV OC43 (hereon hCoV 229E + OC43), hCoV HKU1 and hCoV NL63 (hCoV HKU1 + NL63), hPIV 1 and hPIV 2 (hPIV 1 + 2), hPIV 3 and hPIV 4 (hPIV 3 + 4), hRV, and AdV. hPIV 3 likely comprises most of hPIV 3 + 4 incidence because hPIV 4 infections are detected infrequently and tend to be mild or asymptomatic ( 24 ).…”
Section: Resultsmentioning
confidence: 99%
“…Due to assay limitations, epidemiologically distinct strains were grouped into one assay each for hCoV 229E and hCoV OC43, hCoV HKU1 and hCoV NL63, hPIV 1 and hPIV 2, hPIV 3 and hPIV 4, EV, hRV, and AdV. hPIV 3 likely comprises most of hPIV 3 + 4 incidences because hPIV 4 infections are detected infrequently and tend to be mild or asymptomatic 63 .…”
Section: Virologic Surveillance and Laboratory Methodsmentioning
confidence: 99%
“…However, several cases of both positive and negative outcomes in nonrandomized studies have been reported. The use of ribavirin medication for the treatment of HPIV infection is not recommended due to the lack of evidence supporting its efficacy in improving clinical outcomes [10,11]. Therefore, there is a need for the development of new antiviral agents that can effectively treat these infections.…”
Section: Introductionmentioning
confidence: 99%